Enlivex Therapeutics (ENLV) Set to Announce Quarterly Earnings on Tuesday

Enlivex Therapeutics (NASDAQ:ENLV) is scheduled to post its quarterly earnings results on Tuesday, April 2nd.

Enlivex Therapeutics Price Performance

Shares of NASDAQ:ENLV traded up $0.07 during midday trading on Monday, hitting $3.86. The company had a trading volume of 53,265 shares, compared to its average volume of 93,610. Enlivex Therapeutics has a twelve month low of $1.20 and a twelve month high of $4.37. The business’s 50-day simple moving average is $3.30 and its 200-day simple moving average is $2.42.

Institutional Investors Weigh In On Enlivex Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ENLV. Bank of America Corp DE grew its position in Enlivex Therapeutics by 87.0% in the first quarter. Bank of America Corp DE now owns 6,163 shares of the company’s stock worth $34,000 after acquiring an additional 2,867 shares during the period. Goldman Sachs Group Inc. purchased a new position in shares of Enlivex Therapeutics during the first quarter worth $68,000. UBS Group AG boosted its position in shares of Enlivex Therapeutics by 73.4% during the third quarter. UBS Group AG now owns 31,871 shares of the company’s stock worth $136,000 after buying an additional 13,490 shares during the period. Finally, Jane Street Group LLC boosted its position in shares of Enlivex Therapeutics by 89.6% during the first quarter. Jane Street Group LLC now owns 52,507 shares of the company’s stock worth $294,000 after buying an additional 24,807 shares during the period. Institutional investors and hedge funds own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.